AteschrangAAlbrechtDSchroeterSWeiseKDoldererJ.Current concepts review: septic arthritis of the knee pathophysiology, diagnostics, and therapy. Wien Klin Wochenschr. 2011;123:191-197.
2.
MargarettenMEKohlwesJMooreDBentS.Does this adult patient have septic arthritis?JAMA. 2007;297:1478-1488.
3.
MathewsCJKingsleyGFieldM. Management of septic arthritis: a systematic review. Ann Rheum Dis. 2007;66:440-445.
4.
SowerwineKJHollandSMFreemanAF.Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250:25-32.
5.
FreemanA.Hyper IgE syndromes and the lung. Clin Chest Med. 2016;37:557-567.
6.
MinegishiYSaitoM.Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome. Ann N Y Acad Sci. 2011;1246:34-40.
7.
MintzRGartyBZMeshelT. Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in hyper IgE syndrome patients. Immunol Lett. 2010;130:97-106.
8.
DeWittCABishopABBuescherLSStoneSP.Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol. 2006;54:855-865. doi:10.1016/j.jaad.2005.10.022.
9.
BardSParavisiniAAvilés-IzquierdoJAFernandez-CruzESánchez-RamónS.Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol. 2008;144:1662-1663. doi:10.1001/archdermatol.2008.510.
10.
ChularojanamontriLWimoolchartSTuchindaPKulthananKKiewjoyN.Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol. 2009;27:233-236.
